Floatz logo

WARFARIN

Cardiovascular Diseases

Seoul National University HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
81/ 100

Competitive context

59 Active assets in the Cardiovascular Diseases cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

WARFARIN is also rated in:

venous thromboembolismDormant
A
Indicative ·
81 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →